Bardoxolone methyl-treated patients with type 2 diabetes had better glomerular filtration rates, a measure of kidney function, compared with those who took a placebo, a study in The New England Journal of Medicine found. Researchers hope the antioxidant drug will delay or prevent the need for dialysis in patients with kidney disease.

Related Summaries